Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Analyst Sees Impax Potential

By Pharmaceutical Processing | March 15, 2011

A potential Parkinson’s disease treatment from Impax
Laboratories Inc. could generate as much as $400 million in annual U.S. sales,
according to a Collins Stewart analyst who raised her price target for the
stock.

Impax, based in Hayward,
Calif., said after the market
closed Monday the drug candidate met key goals in a late-stage study focused on
patients with fluctuations in motor function. Impax plans to present the full
study on the potential treatment, labeled IPX066, at an upcoming scientific
meeting.

The company plans to file an application for the drug’s
approval in the fourth quarter and expects approval in late 2012, according to
analyst Louise Chen.

“This is great news for (Impax) since IPX066
diversifies the company’s revenue away from solely generics,” the analyst
wrote in a research note Monday.

Company shares rose $1.93, or 8.7 percent, to $24 in
pre-market trading Tuesday.

Chen said IPX066 could contribute up to $3 a year to the
company’s earnings per share. The analyst estimates the drug could reach peak
annual U.S. sales of between
$200 million and $400 million and may see a similar figure outside the United States,
where it is partnering with British drugmaker GlaxoSmithKline Plc.

Chen reiterated a buy rating on the stock and raised her
price target for shares to $26 from $23.

 

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE